Recovering vision in corneal epithelial stem cell deficient eyes by Bains, Kiranjit Kaur et al.
Contents lists available at ScienceDirect
Contact Lens and Anterior Eye
journal homepage: www.elsevier.com/locate/clae
Recovering vision in corneal epithelial stem cell deficient eyes
Kiranjit K. Bainsa, Hideki Fukuokab, Greg M. Hammonda, Chie Sotozonob,
Andrew J. Quantocka,b,⁎
a Structural Biophysics Group, School of Optometry and Vision Sciences, Cardiff University, Maindy Road, Cardiff, Wales, United Kingdom
bDepartment of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kamigyo-ku, Kyoto 602-8065, Japan
A R T I C L E I N F O
Keywords:
Cornea
Corneal epithelium
Ocular surface disease
Limbal stem cell deficiency
A B S T R A C T
A healthy corneal epithelium, which is essential for proper vision and protection from external pathogens, is
continuously replenished throughout life by stem cells located at the limbus. In diseased or injured eyes,
however, in which stem cells are deficient, severe ocular problems manifest themselves. These are notoriously
difficult to manage and as a result the last 20 or so years has seen a number of therapeutic strategies emerge that
aim to recover the ocular surface and restore vision in limbal stem cell deficient eyes. The dominant concept
involves the generation of laboratory cultivated epithelial cell sheets expanded from small biopsies of the epi-
thelial limbus (for patient or donors) or another non-corneal epithelial tissue such as the oral mucosa. Typically,
cells are grown on sterilised human amniotic membrane as a substrate, which then forms part of the graft, or
specially formulated plastic culture dishes from which cells sheets can be released by lowering the temperature,
and thus the adherence of the plastic to the cells. Overall, clinical results are promising, as is discussed, with new
cultivation methodologies and different cell lineages currently being investigated to augment the treatment
options for visual disturbance caused by a corneal epithelial limbal stem cell deficiency.
1. Introduction
A healthy corneal epithelium is essential for vision. Patients often
present with conditions that impact negatively on the integrity of the
ocular surface and these can include minor abrasions, allergies, kera-
titis, dry eye, ocular herpes, and pterygium to name just a few.
Treatment regimens for these conditions often involve a pharmacolo-
gical approach. However, when the epithelium is defective owing to
limbal stem cell deficiency, treatment is notoriously difficult. Corneal
epithelial stem cells are widely believed to reside in the basal epithe-
lium at the limbus [1,2]. Certainly, not all epithelial cells in the limbal
basal epithelium are stem cells, and whilst there seems to be no agreed
consensus as to what proportion might be stem cells in the healthy eye,
it is reasonable to conclude that there must be sufficient numbers to
counteract the loss of superficial central corneal epithelial cells into the
tear film. As described elsewhere [3,4], the corneal epithelium is able to
be continually replenished because stem cells undergo asymmetric cell
division, producing two daughter cells; one remains as a stem cell
whilst the other becomes a transient amplifying cell. In the corneal
epithelium these transient amplifying cells migrate inwardly over the
corneal surface from the limbus, becoming fully differentiated corneal
epithelial cells as they do so [2]. But, in the absence of an adequate
number of limbal stem cells to act as a reservoir for the corneal epi-
thelium, the ocular surface becomes severely compromised. Some
contemporary approaches to treat vision loss caused by corneal epi-
thelial stem cell deficiency exist and will be described as follows.
2. Corneal epithelial limbal stem cell deficiencies
A corneal epithelial limbal stem cell deficiency can arise because of a
thermal or chemical burn, extensive mechanical trauma, inflammatory
disease, contact lens wear, and/or iatrogenic trauma [5,6]. Clinically, it
can be manifested by the presence of corneal neovascularisation, chronic
inflammation, conjunctivalization, and/or a persistent epithelial defect.
Importantly, autoimmune conditions such as Stevens-Johnson syndrome
and ocular cicatricial pemphigoid exhibit severe ocular surface pathology
related to a limbal epithelial stem cell deficiency and have links to in-
fectious keratitis [7]. A recent ten-year retrospective analysis of 1331
patients with limbal epithelial stem deficiencies in two major eye hos-
pitals in India by Vazirani and associates [8] reported that most patients
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presented with a unilateral stem cell deficiency (791 patients versus 540
with bilateral deficiencies) and that ocular surface burns were the most
common identifiable cause of these at almost 85%. Exposure to lime,
used in the construction industry, caused over 60% of these injuries, but
this is likely to be lower in the UK because of more stringent safety
practices. The leading identifiable causes of bilateral stem cell defi-
ciencies, on the other hand, were ocular surface burns (30%), allergic
conjunctivitis (29%), Stevens-Johnson syndrome or toxic epidermal ne-
crolysis (23%), aniridia (9%), and mucous membrane pemphigoid (4%).
It is important for the clinician to note that individuals with com-
promised limbal stem cell function often present with symptoms that
include reduced vision, photophobia, and varying degrees of ocular
discomfort [5,9–11]. Conjunctivalization of the ocular surface also oc-
curs [12], and this can be recognised upon slit lamp examination by the
appearance of varying amounts of superficial neovascularisation, cor-
neal opacification/scarring and, on occasion, a reduced tear film break
up time [5,6,11]. The conjunctival epithelium that covers the cornea is
more permeable than the corneal epithelium [13], and this can lead to a
characteristic “late” fluorescein staining of the cornea, when the
staining is not detected initially after fluorescein instillation, but is
observed 10–15minutes later [5,9]. Whatever the underlying cause(s)
of a corneal limbal epithelial stem cell deficiency treatment is extremely
challenging, with early identification and referral is likely to be bene-
ficial to access new surgical approaches that are helping to address the
problem (Figs. 1and 2).
3. Ocular surface reconstruction in limbal stem cell deficient eyes
Over the past two decades or so since the pioneering work of
Pellegrini, Tsai, Kinoshita and others, the innovative use of limbal
transplantation techniques using allogeneic or autologous tissue sources
– that is, respectively, cells that are foreign to the patient (donor-de-
rived), or cells that are secured from the patient themselves – has shown
considerable promise for the cultivation of epithelial stem cells to
generate cell-based constructs for the reconstruction of the ocular sur-
face [14–16]. The underlying concept is that the transfer of ex vivo
expanded epithelial multi-layers onto the eye will repair and regenerate
the stem cell deficient corneal surface to facilitate renewed epithelial
healing, regression of vascularization, and prevention of recurrent
erosion [17,18].
Researchers have investigated several ways of generating stratified and
functional corneal epithelial cell sheets. An explant culture system was
among the first procedures to be used and involves the placement of a
small limbal biopsy of healthy tissue onto sterilised portions of human
amniotic membrane (i.e. the inner part of the human placenta), which acts
as the substrate for ex vivo cell expansion. Corneal epithelial cells migrate
from the biopsy and adhere to the amniotic membrane, which then serves
as a carrier to physically support the expanded cell sheet as it is trans-
planted, along with the amniotic membrane substrate, onto the diseased
ocular surface, once any fibrous scar tissue has been removed from the
front of the diseased or injured cornea. Generally, around two-weeks
cultivation in the laboratory is sufficient to obtain a stratified corneal
epithelium [16,17]. Animal experiments have shown that the amniotic
membrane can persist in the cornea for a significant period of time [19],
but clinical experience does not tend to report a detrimental effect of the
amniotic membrane remaining on the eye after ocular surface re-
constructive surgery, possibly owing to the thin, almost transparent nature
of the membrane itself. It is also possible that the amniotic membrane
might aid the healing process via growth factors which are present within
it [20]. The majority of early work expanding corneal epithelial cells in-
volved a co-culture system, which incorporated a growth-arrested 3T3
fibroblast feeder layer underlying the amniotic membrane to help promote
epithelial differentiation [21]. However, this is now seen to be sub-op-
timal, especially if the fibroblasts have a non-human animal origin. A
modification of the explant approach is a suspension culture system, which
utilizes enzymes (typically dispase and trypsin), to isolate limbal epithelial
cells from the rest of the limbal biopsy to form a cell suspension [22].
These cells are then cultured, as before, until confluent cell sheets are
formed after incubation for 12 or more days, which can be transplanted on
to the ocular surface [23]. Based on the published literature it appears as
though both the explant and cell suspension culture systems are effective
tools for ocular surface reconstruction using allogenic and autologous cell/
tissue sources, although the cell suspension method seems, nowadays, to
be more widely employed.
Cells grown in laboratory conditions respond to the properties of the
substrate upon which they are cultivated and the chemical environment
provided by the culture media that sustains them. Human amniotic
membrane is often used to promote the ex vivo expansion of corneal
limbal epithelial cells and has become a stable in many studies. This is
because, as with other materials such as collagen membranes, it can
Fig. 1. Clinical photographs of the patient's eye
before (A,B) and after (C,D) allogenic culti-
vated limbal epithelial transplantation (CLET).
Ocular surface squamous neoplasia (OSSN) re-
curred and covered the entire corneal surface
at 6-years post tumor resection (A). Fluorescein
staining of the same eye showed an irregular
ocular surface (B). CLET was performed com-
bined with tumor resection, and phacoemulsi-
fication and intraocular lens transplantation
(PEA+ IOL). At 1-year post CLET, the cornea
was covered by healthy corneal epithelial cells
derived from the transplanted cultured corneal
epithelial cell sheet (C). Fluorescein staining
showed a smooth and stable corneal surface
(D). Best-corrected visual acuity (BCVA) im-
proved from 0.15 to 0.7.
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support epithelial growth [24], and its use is thought to help improve
wound healing via a prevention of corneal scarring [16]. The amniotic
membrane, itself, is basically a thin connective tissue, which is pos-
sessed of its own epithelium. Some researchers favour leaving the am-
niotic epithelium intact when expanding limbal epithelial cells on
amniotic membrane, which is claimed to promote a corneal epithelial
phenotype [25]. Other groups, in contrast, recommend its removal to
likely facilitate better epithelial adherence [26–28], and this tends to be
the common contemporary approach.
An alternative to the use of amniotic membrane as a substrate and
carrier is the use of a temperature-responsive polymeric culture surface
on which the corneal epithelial multi-layer can be formed. The chem-
istry of the polymer is such that when its temperature is reduced below
a critical solution temperature, then the epithelial cell multi-layer loses
adherence and is able to be readily detached and used, carrier-free, to
reconstruct the exposed corneal stroma from which fibrotic tissue has
been removed [29,30]. This approach has the perceived advantage of
allowing direct interaction between the expanded epithelial multi-layer
and the recipient’s ocular surface, without an intervening carrier con-
struct. In addition to intact and denuded amniotic membrane and
temperature-responsive polymers a number of other viable substrates
for the ex vivo expansion of epithelial cell multi-layers, such as col-
lagen- and fibrin-based carriers, have also been investigated for ocular
surface reconstruction and reviews of these can be found elsewhere
[31,32].
The nutrient media with which the expanded epithelial cells are
nourished is also important for their growth and differentiation. Often,
both explant and cell suspension cultivation protocols have used xe-
nobiotic (i.e. cross-species) materials, such as murine-derived feeder
cells and bovine serum. Indeed, over the past two decades, the use of
foetal calf serum and murine-derived 3T3 fibroblasts, combined with
Dulbecco’s Modified Eagle Medium, has become routine in the majority
of approaches to refine techniques to expand epithelial cells into
transplantable tissues. The use of non-human materials, however, has
raised safety concerns regarding potential transmission of cross-species
viruses and prions, and as a consequence, experiments have been
conducted in an attempt to determine alternative xenogeneic-free
substitutes to improve upon the established culture systems. Nakamura
and associates, for example, investigated the efficacy of autologous
human serum as a feasible replacement for fetal bovine serum and,
encouragingly, found it to have equivalent results [33]. Kolli and co-
workers also achieved successful expansion of epithelial cells with the
use of a non-animal derived serum for the treatment of chemical burns
to the ocular surface [34], whilst Sangwan and associates generated
autologous cultivated limbal epithelial sheets using xeno-free explant
culture techniques to treat unilateral total limbal stem cell deficiency
and achieved an overall success rate of 71%, with a better than 60%
improvement in visual acuity [35]. Most recently, Nakamura and co-
workers were able to develop a novel feeder-free and serum-free tech-
nique to engineer transplantable tissue for the treatment of the dys-
functional ocular surfaces of rabbits that survived for up to two weeks
[36]. Collectively, these advances represent key steps towards gen-
erating laboratory-grown cell constructs to treat ocular surface disease.
But, what are the surgical techniques currently employed?
4. The cell source for corneal epithelial reconstruction using ex
vivo expanded cell constructs
At the present time, the two most common forms of ocular surface
reconstruction using expanded epithelial multi-layers are Cultured
Limbal Epithelial Transplantation (CLET) and Cultured Oral Mucosal
Epithelial Transplantation (COMET). In the case of CLET autologous
and allogeneic cells are utilised, whereas in the case of COMET only
autologous cells are employed. It is evident from the published litera-
ture that both CLET and COMET are associated with favourable clinical
outcomes and based on current knowledge it is difficult to judge one
approach to be manifestly superior to the other. Generally, COMET is
performed for the end-stage severe ocular surface diseases such as
Stevens Johnson syndrome, ocular cicatrical pemphegoid or a che-
mical/thermal burn to release symblepharon and/or replace severely
damaged ocular surface cells. It is worth noting that the use of tear
exchangeable rigid contact lenses was able to improve the visual out-
come following COMET [37].
4.1. Cultured limbal epithelial transplantation (CLET)
For allogeneic CLET, limbal stem cells are obtained from tissue
biopsied from either a living relative or donor eye, with the small tissue
biopsy extending about 1mm either side of the corneoscleral junction
[38]. After the graft, vigilant postoperative care with long-term
Fig. 2. Clinical photographs of the patient's eye
before (A) and after (B,C,D) autologous culti-
vated oral mucosal epithelial transplantation
(COMET). COMET was performed combined
with keratectomy, amniotic membrane trans-
plantation, and PEA+ IOL for end-stage ocular
pemphigoid with keratinization and sym-
blepharon (A). Symblepharon was successfully
released, and non-keratinized epithelium de-
rived from the cultivated oral mucosal epithe-
lial cell sheet covered the entire corneal surface
at 3-years post COMET (B), and BCVA im-
proved from hand motion to count fingers post
COMET. Fluorescein staining of the same eye
post-COMET showed no epithelial damage (C).
COMET enabled the use of a tear-exchangeable,
limbal, rigid CL, and BCVA improved to 0.05
via the use of this CL (D).
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Table 1
Summary of Published Studies Using Limbal Epithelial Stem Cells.
ARTICLE (ref) NUMBER OF
EYES/Px
AUTO/
ALLO-
GRAFT
TISSUE
TYPE
FEEDER
CELL LAYER
SUBSTRATE PATHOLOGY MEAN FOLLOW
UP (MONTHS)
VA IMPROVEMENT* SUCCESS
RATE*
Tsubota et al. 1999
[70]
43/39 Allo LESC N AM SJS/OCP 25
Therm/Chem 14
28.2 60% –
Schwab et al. 2000
[43]
14/14 Auto 10
Allo 4
LESC
LRD
Y D-AM NS 13 – 71.4%
Tsai et al. 2000 [15] 6/6 Auto LESC N AM Chem 3
Other 3
15 83% –
Koizumi et al. 2001
[27]
13/11 Allo CAD Y D-AM SJS 7
OCP 2
Chem 3
Other1
11.2 – –
Grueterich et al. 2002
[71]
1/1 Auto LESC N AM Chem 1 21 – –
Shimazaki et al. 2002
[44]
13/13 Allo CAD 7
LRD 6
Y AM SJS 8
OCP 3
Chem 2
NS – 46.2%
Sangwan et al. 2003
[72]
2/1 Auto LESC Y D-AM Chem 1 12 – –
Nakamura et al. 2004
[73]
1/1 Auto LESC Y D-AM Chem 1 19 – 100%
Daya et al. 2005 [23] 10/10 Allo CAD 9
LRD 1
Y AM SJS 3
Therm/Chem 3
Other 4
28 40% 70%
Nakamura et al. 2006
[33]
9/9 Auto 2
Allo 7
LESC
CAD
Y D-AM SJS 2
OCP 1
Chem 1
Aniridia 1
Idiopathic 2
Other 2
14.6 100% 100%
Sangwan et al. 2006
[74]
88/86 Auto LESC N D-AM Therm/Chem 78
Other 10
18.3 – 73.1%
Ang et al. 2007 [75] 2/1 Allo CAD Y D-AM SJS 1 NS – –
Fatima et al. 2007
[76]
1/1 Auto LESC Y AM Chem 1 37 – 60%
Shimazaki et al. 2007
[77]
27/27 Auto 7
Allo 20
LESC
CAD 12
LRD 8
N
Y
D-AM
AM
SJS 13
OCP 4
Therm/Chem 9
Other 1
29.2 48.1% 59.3%
Kawashima et al.
2007 [78]
6/6 Auto 2
Allo 4
LESC
LRD 1
CAD 3
Y
Y
D-AM Chem 3
SJS 2
Pseudo-OCP 1
6.8 – –
Shortt et al. 2008 [79] 10/10 Auto 3
Allo 7
LESC
CAD
N AM Chem 4
Aniridia 3
ED 1
Reiger’s
Anomaly 1
Other 1
13 – 60%
Kolli et al. 2009 [80] 8/8 Auto LESC Y AM NS 19 62.5% 100%
Meller et al. 2009
[81]
1/1 Allo LRD NS AM Other 1 31 – –
Satake et al. 2009
[82]
1/1 Auto LESC Y D-AM Other 1 43 – –
Baradaran-Rafii et al.
2010 [83]
8/8 Auto LESC N D-AM Therm/Chem 8 34 – –
Thanos et al. 2010
[84]
1/1 Auto LESC N AM Other 1 28 – –
Sangwan et al. 2011
[35]
200/200 Auto LESC N D-AM Therm/Chem
200
36 60.5% 71%
Sharma et al. 2011
[85]
50/50 Auto 34
Allo 16
LESC 34
CAD 9
LRD 7
N D-AM Therm/Chem 18
Other 2
NS 30
11 68% 74%
Basu et al. 2012 [86] 50/50 Auto LESC N D-AM Therm/Chem 50 27.6 76% 66%
Prabhasawat et al.
2012 [87]
19/18 Auto 12
Allo 7
LESC
CAD
N D-AM Therm/Chem 13
SJS 1
Other 5
26.1 68.4% 73.7%
Pathak et al. 2012
[11]
9/9 Auto LESC N AM Therm/Chem 8
Other 1
11-28 – 55.6%
Sejpal et al. 2013 [88] 107/107 Auto LESC N D-AM Therm/Chem
107
41.2 54.2% 46.7%
Sharma et al. 2013
[89]
4/4 Auto LESC NS D-AM Therm/Chem 4 19.5 100% –
Subramaniam et al.
2013 [90]
40/39 Auto LESC N D-AM Therm/Chem 36
Other 4
33 38% –
(continued on next page)
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immuno-suppressants is required to avoid immunological rejection of
transplanted epithelium [39], notwithstanding the risk of associated
complications. The alternative is to use autologous limbal stem cells,
which, of course, is contingent on the availability of healthy limbal
tissue in an unaffected eye, and thus is only an option for the treatment
of unilateral ocular surface disorders. As seen in Table 1, numerous
articles have described the use of allogeneic and autologous stem cell
sources to expand ex vivo limbal epithelial cells to repair the ocular
surface [22,40–42]. Although post-operative complications following
CLET can occur and have to be guarded against [23,27,43–45], it re-
presents a viable method of treating severely damaged limbal stem cell
deficient eyes.
4.2. Cultured oral mucosal epithelial transplantation (COMET)
To conduct cultured oral mucosal epithelial transplantation, stem
cells are acquired from the interior buccal mucosal epithelium (inner
cheek cells). First reported in 2004 [29,46], this approach has become
something of a catalyst in the search for autologous stem cells as an
alternative to limbal epithelial stem cells. This is especially important in
the case of bilateral injury or disease, where no autologous limbal
epithelial cells are available. To conduct the procedure, buccal mucosal
epithelium is surgically extracted from the inner oral cavity and treated
with dispase and trypsin to form a cell suspension. As described by
Nishida and associates [29], this suspension is seeded onto a tem-
perature-responsive cell-culture insert containing 3T3 feeder cells and
incubated for two weeks to generate a cell sheet that can be released
from the temperature-responsive culture surface by lowering the tem-
perature and transplanted onto the ocular surface. As seen in Table 2,
COMET has been employed by a number of groups with generally po-
sitive outcomes. A recent study by Nakamura and co-workers [47], for
example, showed that oral mucosal cell sheets grown on amniotic
membrane completely covered the membrane and displayed morpho-
logical features that resembled those of a normal corneal epithelium.
When used surgically to treat limbal stem cell-deficient eyes, all with a
pre-operative visual acuity (VA) of worse-than 20/500, the authors
found a 95% improvement in VA overall. The follow-up period in this
study ranged from 36–39 months, and it was the first to demonstrate
the long-term effectiveness of COMET for ocular surface reconstruction.
Other research, too, supports the claims of COMET as novel surgical
therapy for treatment of severe ocular surface disease, especially for
bilateral conditions such as ocular cicatricial pemphigoid, Steven
Johnson syndrome, and chemical injury [48–52].
5. Future potential therapies and cell sources
As mentioned, research with non-corneal stem cells, such as those of
the oral mucosa, has been a catalyst for new and exciting investigations
into potential alternative non-ocular cell sources for the treatment of
ocular surface dysfunction. Investigations of some of these proposed
alternatives are described below.
5.1. Murine vibrissal hair follicle bulge-derived stem cells
Hair follicle bulge-derived stem cells can be isolated and cultured
fairly readily [53]. Indeed, investigators have demonstrated the trans-
differentiation potential of murine vibrissal hair follicle bulge-derived
stem cells as a potential autologous stem cell source for ocular surface
repair, based on their ability to assume corneal epithelial-like proper-
ties when exposed to a corneal limbus-specific microenvironment in
vitro [54]. Subsequent work found that these hair follicle-derived cell
constructs could be used to reconstruct damaged corneal epithelia in
mice [55]. Specifically, the research found a significant reduction in
corneal fluorescein staining four weeks after receiving the bulge-de-
rived stem cell graft when compared to control mice not having re-
ceived the transplant. This suggests that the bulge-derived stem cells
were able to re-form tight intercellular junctions for successful corneal
resurfacing. Similarly, the authors reported that eyes receiving bulge-
derived stem cell transplants had close phenotypic resemblance to that
of normal corneal epithelium, averaging 3–5 cellular layers of differ-
entiated cells. They established an 80% success rate in graft trans-
plantation. Twenty percent of eyes developed a minor degree of con-
junctivalisation near the peripheral aspects of the cornea, however,
with a 5-week follow-up period, no graft rejection was observed. These
results suggest that hair follicle bulge-derived stem cells have the po-
tential to reconstruct the corneal surface in a limbal stem cell deficiency
murine model, but further investigation is required to refine and im-
prove the overall efficacy of the cell source for clinical application.
5.2. Human immature dental pulp stem cells
Human deciduous teeth express markers for mesenchymal stem
cells, embryonic stem cells, and limbal stem cells. Monteiro and co-
workers cultured human immature dental pulp stem cells to produce a
Table 1 (continued)
ARTICLE (ref) NUMBER OF
EYES/Px
AUTO/
ALLO-
GRAFT
TISSUE
TYPE
FEEDER
CELL LAYER
SUBSTRATE PATHOLOGY MEAN FOLLOW
UP (MONTHS)
VA IMPROVEMENT* SUCCESS
RATE*
Qi et al. 2013 [91] 42/41 Allo CAD Y D-AM Therm/Chem 41 12 – –
Amescua et al. 2014
[45]
4/4 Auto LESC N AM Chem 2
Trauma 1
Melanoma 1
7.5 100% 100%
Qi et al. 2014 [92] 16/15 Allo CAD Y D-AM Therm/Chem15 12 – 80%
Vazirani et al. 2014
[93]
70/70 Auto LESC N D-AM Therm/Chem 64
OCP 1
Idiopathic 1
Other 4
17.5 – –
Zakaria et al. 2014
[94]
18/12 Auto 15
Allo 3
LESC
CAD 1
LRD 2
N D-AM Chem 7
Aniridia 2
Other 9
24 – 67%
Ramírez et al. 2015
[95]
20/19 Auto 11
Allo 9
LESC
CAD
N D-AM Chem 7
SJS 3
Aniridia 2
Other 8
36 – 80%
AM=Human Amniotic Membrane. Allo=Allograft. Auto=Autograft. CAD=Cadaver. Chem=Chemical. D-AM=Denuded Human Amniotic Membrane.
ED=Ectodermal Dysplasia. LESC=Limbal Epithelial Stem Cells. LRD=Living Relative Donor NS=Not Stipulated. OCP= ocular cicatricial pemphigoid.
Px= Patient. SJS= Steven Johnson syndrome. Therm=Thermal. VA=Visual Acuity.
* Areas void of information are the result of values not explicitly being provided in the relevant journal articles.
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well-formed corneal epithelium, which was capable of restoring corneal
clarity and smoothness in a rabbit model of corneal epithelial dys-
function and forming an epithelium that exhibited a comparable mor-
phology to that of the normal corneal epithelium [56,57].
5.3. Umbilical cord stem cells
Umbilical cord stem cells have gained attention in the field of re-
generative medicine because, as well as being multipotent, they are
immunologically naïve, thus reducing the risk of possible infection and
immunological rejection. Studies by Reza and associates used umbilical
cords from healthy women undergoing delivery to cultivate umbilical
cord stem cell-derived transplantable sheets for grafting onto the da-
maged eyes of rabbits. Eyes transplanted with umbilical cord stem cells
cultivated on human amniotic membrane, compared to denuded human
amniotic membrane, recovered a smooth and clear corneal surface with
a multi-layered epithelium and minimal opacification and neovascu-
larisation [58,59].
5.4. Embryonic stem cells
Embryonic stem cells are pluripotent cells with the ability to de-
velop into more than 200 different cell types that make up the adult
human body. They derive from epiblast tissue of the inner cell mass of a
blastocyst and when given the necessary stimulation, specific cell-type
differentiation is initiated. Initial studies applying embryonic stem cells
to ocular surface reconstruction by Homma and associates reported
grafts of expanded embryonic stem cells onto the damaged corneas of
six mice [60]. Comparing the transplant-recipient group to the control
group found expression of cytokeratin 12, a specific marker for corneal
epithelial cells, and Pax-6, a transcriptional factor which is necessary
for development of the eye. Eyes chemically damaged with n-heptanol
showed complete epithelial loss, but within 24 h of transplantation,
complex layering consisting of all epithelial cell types was observed
across the entirety of the damaged area. These findings acted as a
foundation for investigations of embryonic stem cell-derived sheets for
ocular surface reconstruction. Subsequent work by Suzuki and collea-
gues in animal models has shown how corneal epithelial cells can be
induced from embryonic stem cells, either by culturing them on type IV
Table 2
Summary of Published Studies Using Oral Mucosal Epithelial Cells.
ARTICLE (ref) NUMBER OF
EYES/Px
AUTO/
ALLO-
GRAFT
TISSUE
TYPE
FEEDER CELL
LAYER
SUBSTRATE PATHOLOGY MEAN FOLLOW UP
(MONTHS)
VA IMPROVEMENT* SUCCESS
RATE*
Nakamura et al. 2004
[46]
6/4 Auto Oral Y D-AM SJS 3
Chem 3
13.8 100% –
Nishida et al. 2004
[29]
4/4 Auto Oral Y TRS SJS 1
OCP 3
14 100% –
Ang et al. 2006 [49] 10/10 Auto Oral Y D-AM Therm/Chem 2
SJS 7
OCP 1
12.6 90% –
Inatomi et al. 2006
[96]
2/2 Auto Oral Y D-AM Chem 1
SJS 1
22.5 – –
Inatomi et al. 2006
[48]
15/12 Auto Oral Y D-AM Therm/Chem 6
SJS 7
Pseudo-OCP1
Other 1
20 67% 67%
Nakamura et al. 2007
[97]
6/5 Auto Oral NS AM SJS 3
Chem 3
NS – 66.7%
Satake et al. 2008 [98] 4/4 Auto Oral Y D-AM SJS 2
Pseudo-OCP 2
6-24 – –
Chen et al. 2009 [99] 4/4 Auto Oral Y D-AM Therm/Chem 4 22 – –
Ma et al.2009 [100] 6/5 Auto Oral Y D-AM Therm/Chem 5 29.6 – –
Nakamura et al. 2010
[47]
19/17 Auto Oral Y D-AM Therm/Chem 1
SJS 11
OCP 4
Other 3
55 95% –
Priya et al. 2011 [101] 10/10 Auto Oral Y D-AM SJS 1
Chem 9
18.6 – –
Takeda et al. 2011
[102]
3/3 Auto Oral Y D-AM Therm/Chem 3 30 – –
Burillon et al. 2012
[103]
26/25 Auto Oral Y TRS Therm/Chem 9
Aniridia 3
Other 14
12 – 64%
Chen et al. 2012 [104] 6/6 Auto Oral Y D-AM Therm/Chem 6 36.7 – –
Sotozono et al. 2013
[52]
46/40 Auto Oral Y AM Therm/Chem 7
SJS 21
OCP 10
Other 8
28.7 48% –
Kolli et al. 2014 [34] 2/2 Auto Oral N AM Chem 2 24 – –
Sotozono et al. 2014
[51]
10/9 Auto Oral Y/N D-AM Therm/Chem 5
SJS 3
OCP 2
23.3 – –
Prabhasawat et al.
2016 [50]
20/18 Auto Oral N D-AM Chem/Therm 7
SJS 10
Others 3
31.9 70% 75%
Allo=Allograft. AM=Human Amniotic Membrane. Auto=Autograft. CAD=Cadaver. D-AM=Denuded Human Amniotic Membrane. Therm=Thermal.
Chem=Chemical. LRD= Living Relative Donor. NS=Not Stipulated. OCP= ocular cicatricial pemphigoid. Px=Patient. SJS= Steven Johnson syndrome.
TRS=Temperature Responsive Surface. VA=Visual Acuity.
* Areas void of information are the result of values not explicitly being provided in the relevant journal articles.
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collagen or by introduction of the Pax6 gene into the embryonic stem
cells, and demonstrated that cells survive when transplanted onto the
cornea [61,62]. One of the characteristics of embryonic stem cells is
that they continue to divide in vitro, with each daughter cell remaining
pluripotent if there are no stimuli for differentiation. The regenerative
potential is thus clear, however, a major hurdle to the use of embryonic
stem cells in regenerative medicine is the valid ethical controversy in-
volved with obtaining cells from extra-fertilised ova used in in vitro
fertilisation (IVF) therapy. Many nations have a moratorium on either
the production of embryonic stem cell lines or embryonic stem cell
research in general, restricting work in this area [63].
5.5. Induced pluripotent stem (iPS) cells
Owing to the ethical concerns surrounding the use of embryonic
stem cells, interest has turned to the possible use of iPS cells in re-
generative medicine, and the eye is no exception. Indeed, the world’s
first transplantation of iPS cells into a human was via the implantation
of an autologous iPS cell-derived retinal pigment epithelium into the
eye of a patient with advanced neovascular age-related macular de-
generation [64]. iPS cells are mature cells that have been repro-
grammed from their differentiated state to an embryonic-like state by
transfer of nuclear contents [65]. Four transcription factors (known as
Yamanaka factors) are capable of generating iPS cells, which exhibit the
morphology and growth properties of embryonic stem cells and express
embryonic stem cell marker genes. It was a pivotal discovery that led to
the award of the 2012 Nobel Prize in Physiology or Medicine to Pro-
fessors Shinya Yamanaka (Kyoto) and John Gurdon (Cambridge).
Contemporary research with human iPS cells has provided encourage-
ment for their potential use in the treatment of eye disease. As well as
the aforementioned studies on retinal pathology [64], the discovery
that human iPS cells could spontaneously form concentric colonies of
cells with ocular characteristics has opened the door to future advances
in the treatment of other parts of the eye, especially the corneal epi-
thelium, with animal models already showing how a functional human
iPS cell-derived epithelial cell sheet can repair severely damaged limbal
stem cell-deficient eyes [66,67].
5.6. Mesenchymal stem cells
Mesenchymal stem cells are non-hematopoietic multipotent cells
derived from bone marrow. They have been used in studies such as
those by Ma and colleagues to examine whether or not human me-
senchymal stem cells could successfully reconstruct the damaged ocular
surface and if grafted mesenchymal stem cells could differentiate into
corneal epithelial cells [68]. After isolating and expanding mesench-
ymal stem cells on amniotic membrane, grafts were transplanted onto
chemically damaged corneas of rats and visual function measured using
an optokinetic head-tracking instrument along with a slit-lamp assess-
ment to determine the corneal status. This research found that of 51
eyes undergoing various treatments (i.e. with mesenchymal stem cells,
limbal stem cells, fibroblasts, amniotic membrane alone, dex-
amathazone, and gentamicin), 16 eyes transplanted with mesenchymal
stem cells on amniotic membrane significantly improved the damaged
corneal surface and resulted in improved vision compared to the other
treatments. An immunofluorescence analysis, however, failed to detect
the expression of corneal epithelial specific cytokeratin K3 in the epi-
thelia of eyes transplanted with human mesenchymal stem cells on
amniotic membrane, suggesting that the efficacy of this treatment was
not dependent on the differentiation of mesenchymal stem cells into
epithelial cells, but was due, in part, to the expression of CD45 and
interleukin 2 (glycoproteins expressed on a majority of bone-marrow
derived cells), which contributed to the inhibition of inflammation and
inflammation-related angiogenesis. More recently, it has been shown
that sufficient stratification and expression of cytokeratins, growth
factors, and tight junction proteins could be achieved in cultivated
sheets obtained from limbal epithelial cells if mesenchymal cells were
used as feeder cells [69], highlighting the versatility of the various cell-
based therapeutic concepts and the need for a carefully thought-out
strategy to achieve optimal ocular surface repair, possibly using dif-
ferent cells, media and substrata in combination.
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